

ALDMSIC UMTED

CIN-L282000229079LC000083 Regd.Office: Alembic Road, Vadodara 200 000 Ph: \$265 9637300

name alember (medical medical medical

Statement of Conselidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2023

-			Quarter Ended		Half Yes	or Endad	Year Ended	
k.		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023	
и. 60	· Particulars	(Unaudited)		[Usoudited]	(Usaudited)		(Audited)	
80	> Muscalina	(Unaucones)	(0,1493100)	[(rejetake]	(Consideration)	(mancane)	(Maarino)	
1	Revenue from Operations	5,228	3,684	3,742	6,912	5,952	12,724	
2	Other income	4,787	263	5,508	5,051	5,978	6,426	
1	Tetal income	8,015	3,547	9,650	11,963	11,930	19,151	
	Capentes							
•	Cost of Materials Consumed	266	134	236	380	432	692	
	Cost of Casstruction	756	523	1,263	1,718	1,724	3.480	
	Charges in inventories of Finished Goods and WIP	06		(109)	189	(112)	650	
		(56) 563	627	634	1.150	1,255	2,404	
	Employee Benefit Expenses			12	27	23	42	
	Finance Costs	13	13	167	370	334	672	
	Depreciation and amortisation expense	186	183		1,881	1,006	2,175	
	Other Expenses	665	665	614	1,881	1,006	2,105	
	Total Expenses	2,412	2,795	2,816	5,206	4,662	9,410	
5	Profit Before Enceptional Rems and Tau (3-4)	5,603	1,155	6,833	6,758	7,269	9,743	
6	Exceptional Items						1,061	
7	Profit Before Tax (5-6)	5,603	1,155	6,833	6,758	7,268	8,680	
۰	Tax Expenses					471	372	
	Current Tax	534	113	436	647			
	Deferred Tax	194	46	273	242	288	247	
	Short / (Kacess) Provision of earlier years	(297)			(267)		- 12	
2	Net Profit after tax for the Period	5,171	995	6,124	6,166	6,509	8,067	
90	Share of Associate's Profit/(Loss)	3,867	3,442	5,429	7,559	3,168	11,00	
11	Net Profit/(Less) after tax and Share of Associate's Profit/(Less)	9,068	4,430	11,533	11,506	9,678	19,065	
12	Other Comprehensive Income				2.00			
	A (i) Items that will not be reclassified to Profit or (Last) (ii) Income tax relating to items that will not be reclassified to Profit.	(3,134)	4,004	(1,407)	830	18,808	(24,613	
	or (l.est)	367	[453]	167	(94)	1,008	2,811	
	0 (4 Items that will be reclassified to Profit or (Loss)	74	(24)	147	49	336	391	
13	Total Comprehensive Income/(Loss) for the Period	6,334	7,945	10,441	14,299	2,204	(2,340	
14	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.6	
15	Other Equity (excluding Revolution Reserve)						1,69,495	
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diksted (in Rs.)	3.53	1.79	4.49	5.26	3.77	7.A	





		ŵ		

			Overter Ended		Half Yes	r Ended	Year Ended
Sr. No	Perioden	30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Usaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
1	Segment Revenue Sevenue from Operations a. Active Pharmacourical Ingredients Business b. Real Solate Business	785 2,442	944 2,740	674 3,068	1,729 5,183	1,409 4,548	2,646
	Total Income from Operations (Net)	3,228	3,684	3,742	6,912	5,952	12,724
2	Signest Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)	10		as.	137	174	203
	a. Active Pharmaceutical ingredients Business	92 869	45 936	971	1.825	1.324	3.607
	b. Real Estate Business	940			1,835		3,900
	Total Unallocable Income and Expenditure	940	1,022	1,017	1,962	1,498	3,500
	(i) interest Expense	(13)	(13)	(12)	(27)	(23)	
	(ii) Exceptional items API						(1,061
	(iii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	4,651	224	5,781	4,775	5,731	5,730
	(ix) Other Income / (Expense)	25	22	41	47	61	157
	Total Profit Before Tax	5,603	1,155	6,833	6,758	7,268	8,680
3	Sogner# Assets a. Active Pharmacoutical Ingredients Business	18,414	18,674	15,318	18,414	15,318	15,278
	b. Real Estate Susiness	33,628	30,800	28,883	33,628	28,883	32,042
	c. Unaflocated	1,74,991	1,79,722	2,11,741	1,74,931	2,11,741	1,73,139
	Yotal	2,24,572	2,29,196	2,55,942	2,26,972	2,55,942	2,20,458
4	Segrecet Liabilities  a. Active Pharmaceutical Ingredients Susiness	2,943	2,918	2,589	2,943	2,589	2,753
	b. Fical Estate Dusiness	8,252	6,527	6,418	8,252	6,418	6,419
	c. Urullocated	3,811	3,983	5,508	3,811	5,508	3,484
	Tetal	15,006	13,428	34,315	15,005	14,315	12,655

Tetal

The above results have been reviewed by Statutiony Auditors, recommended by Audit Committee and approved by the Soard of Directors of the Company. 2 Exceptional form for the year ended 31st March, 2023 represents provision made by the Company towards balance of the principal amount flotal principal amount being Rs. 2,052.13 liable) for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as continuent liability. Further, as communicated by the Company with the stock exchanges vide its letter dated 15th May, 2023, the

Congary has deposited its. 35 Crores with the Hon'tile Supreme Court of India on 20th May, 2023 and the appeal filed by the Congary has been admitted. 3. The provious quarter's / year's figures have been regrouped / repropaged wherever necessary to make it comparable with the current quarter / year.

Place : Varietore Date ( 08th November, 2022)







Chalyman

Statement of Consolidated Assets and Liabilities		Rs. in Lakhs
Particulars	As at 30th September, 2023 (Unaudited)	As at 31st March, 2023 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipments	13,117	13,183
(b) Capital Work in Progress	54	13
(c) Investment Property	21,297	18,942
(d) Goodwill	5	5
(e) Financial Assets		
(§ Investments	38,525	37,432
(ii) Investments accounted using Equity Method	1,36,225	1,33,394
(III) Others	287	285
(f) Other Non-Current Assets	3,500	
	2,13,010	2,09,245
Current Assets		
(a) Inventories	8,654	8,861
(b) Financial Assets		
(i) investments	146	4,540
(ii) Trade Receivables	2,152	2,345
(iii) Cash and Cash Equivalents	188	93
(iv) Bank Balances other than Cash and Cash Equivalents	129	97
(v) Others		410
(c) Other Current Assets	1,434	78
(d) Current Tax Assets (Net)	13,962	17,214
TOTAL - ASSETS	2,26,972	2,20,458
EQUITY AND LIABILITIES		
fquity		
(a) Equity Share Capital	5,136	5,136
(b) Other Equity	2,96,830	2,00,668
	2,11,965	2,07,809
Liabilities		
Non-Current Liabilities		
(a) Financial Uabilities		
()) Europeings	416	
(II) Other Financial Liabilities	637	670
(b) Provisions	169	121
(c) Deferred Tax Liability (Net)	5,003	3,484
Current Liabilities		
(n) Financial Liabilities		
() Dorrowings	1 14	
(II) Trade Payables	229	311
a) total outstanding dues of Micro and Small Enterprises	2,755	1.42
b) total outstanding dues of Others	757	639
[8] Other Financial Uabilities	3,988	3,87
(b) Other Current Liabilities	2,460	2.1%

Place : Vadodara Date : 68th November, 2023





2,26,972

### Alembic Limited

Consolidated Code flow Statement for Malf Year and od 20th Contomber 201

		Fs. In Lakfe
	For the Half Year	For the Half Year
Particulars	Ended on 30th	Ended on 30th
Participan	September, 2023	September, 2022
	(Unaudited)	(Unsedited)
CASH FLOW FROM OPERATING ACTIVITIES:		
Net Profit before tax	6,758	7,268
A44: *		
Depreciation	570	884
Interest chursed	27	23
(Soin) / Loss on sale of Property, Plant and Equipments	(16)	5
Sundry balances written back (Net)		
Other Non cash items	(187)	121
Lens		
Interest Income	(35)	(57
Dividend income	(4.591)	(3,686
Operating Profit before change in working capital	2,821	1,826
Warking capital charges:	4111	
Add / (Less) :		
(Increase) / Decrease in Inventories	206	(72
Encrease) / Decrease in Inventories Encrease) / Decrease in Trade Receivables	193	(536
	(4,534)	25
(Increase) / Decrease in Other Asset (Increase) / Decrease in Financial Asset	(292)	633
	1,347	(147
Increase / (Decrease) in Trade Payables	56	06
locresse / (Decresse) in Financial Usblittics	100	1,600
Increase / (Decrease) in Other Liabilities		
Increase / (Decrease) in Provisions	52	43
Cash generated from operations	(651)	3,531
A66 / (Less) :		100
Direct taxes paid (Net of refunds)	(452)	
Net cash inflow from operating activities (A)	(1,678)	3,036
CASH FLOW FROM INVESTING ACTIVITIES:		
Aff		
Proceeds from sale of Property. Plant and Equipments	38	- 14
Proceeds from sale / redemption of investments	11.161	5.850
Internal received	39	50
Dividend received	4,591	5,688
Less	35,500	. 11,590
Min.		
Purchase of PPC and Investment Property/Increase in CNIP and Capital Advances	2,786	920
Purchase of investments	6.566	9.09
hypease in Restricted Bank Salances other than Cash & Cash Equivalents	32	60
to design a separation of the	9,699	90,07
Net cash inflow from Investing activities (8)	6.812	1,525
C CASH FLOW FROM FINANCING ACTIVITIES	4,510	- 1000
Add	500	
Proceeds from long term borrowings	500	
Lesse	5417	4.56
Chidends paid	5,617	4.54
Interest and other finance costs		
	5,644	4,58
Not each inflow from Financing activities (-C)	(5,144	14.58
and constrained account of	10000	1000
	95	0.
Net (Decresse) / Incresse in cash and cash equivalents (A+8+C)	- 29	
IL. Cash and cosh equivalents at the beginning of the period	41	11
r can ma can oponion or me reprint a me posse		
Bi. Cash and cash equivalents at the end of the period (IHB)	- 188	9
W. Cash and cash equivalents at the end of the period		
Belances with Bank	187	1
Cash on Wand		
Cash and cash equivalents	188	9

face : Vadodara late : 08th November, 3525







ALEMBIC LIBERTED
ON::26306::19079L000033
Regd-Office: Hembic Read, Vadodare 550 003

Ph-COSS-6657500 www.standardoniant.com. Email standar investmediatembir on in

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended 50th September, 2023

			Ouarter Ended		Holf Yes	r Ended	Year Ended	
Sr. No.	Particulars	30.09.2023	30.05.2023 (Utaudited)	30.09.2022	30.09.2023 (Unaudited)	50.09.2022	31.03.2023 [Audited]	
1	Revenue from Operations	8.115	3.565	3,639	6,600	5.752	12.316	
•	November transpersions	-	1,040		4,000			
2	Other Income	4,786	259	5,906	\$,045	5,578	6,411	
1	Total income	7,901	3,824	9,545	11,725	11,729	18,727	
	fixeroes							
	Cost of Materials Consumed	246	134	236	380	432	603	
	Cost of Construction	796	923	1,263	1,718	1,724	3,480	
	Changes in Inventories of Finished Goods and WIP	(54)	247	(109)	189	(112)	460	
	Creployee Benefit Expenses	563	627	634	1,190	1,255	2,464	
	Finance Costs	5	5	4	10		34	
	Depreciation and amortisation expense	177	176	258	351	336	636	
	Other Expenses	606	623	549	1,229	934	2,000	
	Total Expenses	2,894	2,733	2,355	5,067	4,537	9,167	
6	Profit Before Exceptional Items and Tax (3-4)	5,566	1,691	6,790	6,658	7,193	9,560	
6	Exceptional Items						1,061	
7	Prefit Before Tax (5-6)	1,566	1,091	6,790	6,658	7,193	8,500	
	Tox Expenses							
	Current Tax	525	96	427	630	451	326	
	Deferred Tax	196	47	275	245	288	248	
	Short / (Cacess) Provision of earlier years	(297)			(297)			
,	Not Profit after tax for the Period	5,145	948	6,090	6,092	6,453	7,923	
10	Other Comprehensive Income							
	(i) Items that will not be reclassified to Profit or (Loss) (ii) Income tax relating to items that will not be reclassified to	(3,117)	4,007	(1,438)	850	(8,811)	(24,603	
	Profit or (Lass)	367	(453)	168	(86)	1,009	2,811	
11	Total Comprehensive Income/(Loss) for the Period	2,394	4,560	4,820	6,866	(1,349)	(13,864	
12	Faid up Equity Share Capital (Face Value of Rs 2/- per share)	5,335.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	
13	Other Equity (excluding Revolution Reserve)						44,554	
	Earnings per equity share (EV Rs. 2/- per share)	2.00	0.37	2.37	2.37	2.51	3.00	
	Basic 8. Ollused (in Rs.)	2.00	0.47	2.87	2.47	2.51	3.00	





	Segment wise Standelone Revenue and Results				Dall'Yes		Re. in Lakh
Se.			Quarter Ended	30.89.2022	36.69.3022	7 Ended	Year Ended
No.	Particulars	\$8.69.2023 [Unaudited]		(Unaudited)	(Unaudited)		(Audited)
1	Segreent Revenue Revenue from Operations						
	s. Active Pharmsceutical Impredients Business	785	944	674	1,729	1,403	2,645
	b. Real Estate Business	2,550	2,621	2,564	4,951	4,348	9,667
	Total Income from Operations (Net)	3,115	3,565	3,639	6,680	5,752	12,316
2	Segrent Results (Frefit (r)/ Less (-) before Taxes and interest from each segrent)						
	a. Active Pharmsceutical impredients Business	52	45	45	137	174	200
	b. Real Estate Susiness	804	905	920	1,708	1,234	3,490
	Total	895	950	966	1,845	1,408	3,689
	Unaflocable Income and Expenditure						
	5) Interest Expense	(5)	(5)	140	(30)	[1]	(16
	III Exceptional items API III Dividend Income and Gain/Illoss) on Fair Value Change of Financial						(1,061
	Asset	4,651	124	5,781	4,775	5,731	5,730
	(iv) Other Income / (Expense)	25	22	48	47	65	153
	Total Profit Before Tax	5,566	1,091	6,790	6,658	7,193	8,500
3	Seament Ameta						
	a. Active Pharmacoutical Ingredients Susiness	18,414	18,674	15,318	18,414	15,318	15,270
	b. Real Estate Business	32,819	30,069	28,060	82,819	28,060	31,134
	c. Unaffected	47,323	51,555	65,884	47,828	65,894	48,407
	Total	98,556	1,00,298	1,09,272	98,556	1,09,272	94,834
4	Segment Liabilities						
	a. Active Pharmaceutical ingredients Business	2,543	2,918	2,389	2,543	2,389	2,753
	b. Fical Extete Business	7,659	5,999	5,884	7,659	5,884	5,684
	c. Unallocated	3,808	3,579	5,585	3,804	5,585	3,470
	Tetal	24.430	12.897	13.858	14,410	13,858	11,916

Notes:

1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2. Successor dates for the year valued lists Match, 2021 requestes provider made for the Company broads Market of the principal reveal (USA) principal reveals (USA) principal reveals (USA) shall for the department and intelligence of company and intelligence of the company of the company with the stock ordinary voider in the company voider in the com

admitted.

3 The provious quarter's / year's figures have been regrouped / rearranged wherever reconsury to make it comparable with the current quarter / year.





Place : Vadodare Oate : O6th Neverber, 2023

itement of Standalone Assets and Liabilities		Rs. in Lakhs
	As at 30th	As at 31st
Particulars	September, 2023	March, 2023
	(Unaudited)	(Audited)
SSETS		
on-current Assets o) Property, Plant and Equipments	13,117	13,183
b) Capital Work in Progress	54	13
c) Lapital work in Progress c) Investment Property	20,569	18.633
d) Financial Assets	20,000	20,000
(é investments	47,200	46,107
(i) Others	165	164
e) Other Non-Current Assets	3.500	104
e) Other Non-Current Assets	85,025	78.099
	-	
arrent Assets		
a) Inventories	8,654	8,861
b) Financial Assets		
(i) Investments		4,160
(ii) Trade Receivables	2,008	2,268
(iii) Cash and Cash Equivalents	135	83
(iv) Bank Balances other than Cash and Cash Equivalents	129	93
(v) Others	1,080	790
(c) Other Current Assets	1,403	400
(d) Current Tax Assets (Net)	123	51
	13,531	16,715
OTAL - ASSETS	98,556	54,814
QUITY AND UABILITIES		
quity		
(a) Equity Share Capital	5,136	5,136
(b) Other Equity	79,010	77,76
	84,145	82,89
abilties		
ion-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	416	
(II) Other Financial Liabilities	177	21
(b) Provisions	160	12
(c) Deferred Tax Liability (Net)	3,606	3,47
Arrent Liabilities	4,569	6,61
(a) Financial Liabilities		
01 Borrowings	84	
60 Trade Payables	-	
a) total outstanding dues of Micro and Small Enterprises	226	30
N total outstanding dues of Others	2,697	1.41
b) total outstanding dues or others (#) Other Financial Liabilities	722	28
(b) Other Financial Liabilities (b) Other Current Liabilities	3.953	3.86
(b) Other Current Liabilities (c) Provisions	2,160	2.13
(C) PTOVISIONS	9,941	8,10
TOTAL - EQUITY AND LIABILITIES	92,556	94,81

Place : Vadodara Date : Gith November, 2023

.

١





### Alembic Limited

Standalone Cash Elow Statement for Half Year ended 30th Sentember 203

	Particulars	Ended on 30th	For the Half Year Ended on 30th September, 2022 [Unaudited]
	CASH FLOW FROM OPERATING ACTIVITIES:	6,658	7,193
	Net Profit before tax Add:	4,430	1,000
	Desirciation	851	316
	Interest charged	10	8
	(Sain) / Loss on sale of Property, Plant and Equipments	0.0	
	(santy) total on sale or Property, Plant and Equipments Sundry balances written back (Net)	(24)	
	Other Non cash items	080	68
	Less:	(in-	, the
	Viterest income	040	660
	Dividend Income	(4,581)	(5,686
	Operating Profit before change in working capital	2.189	1,718
	Working copital changes:	2,445	20.00
	Add / (Less) :		
	(Increase) / Decrease in Inventories	206	172
	[Increase] / Decrease in Trade Recovables	260	1299
	(Increase) / Decrease in Other Asset	(4,497)	
	(Increase) / Decrease in Financial Asset	(292)	
	Increase / (Decrease) in Trade Payables	1,203	050
	Increase / (Decrease) in Trace Payables Increase / (Decrease) in Financial LightRifes	269	
	Increase / (Decrease) in Other Liabilities	92	1.580
	Increase / (Decrease) in Provisions	52	42
	Cash generated from operations	(517)	
	Add / (Less):	1000	2,111
	Add / (Last): Direct taxes paid (Net of refunds)	(395)	(456
	Direct States pand (Net of refunds) Not cash inflow from operating activities (A)	(952)	3.047
,	CASH FLOW FROM INVESTING ACTIVITIES:		
	Add:		
	Proceeds from sale of Property, Plant and Equipments	38	(4
	Proceeds from sale / redemption of investments	11,046	5,755
	Interest received	38	66
	Dividend received	4,591	5,690
	Less	15,692	11,497
	Purchase of FFE and investment Property/Increase in CWP and Capital Advances	2,684	523
	Purphase of Investments	6,886	9,000
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents	52	- 4
		9,602	9,580
	Net cash inflow from investing activities (II)	6,090	3,536
c	CASH FLOW FROM FINANCING ACTIVITIES:		
	Add		
	Proceeds from long term borrowings	500	
	Leng		
	Dividends need	5,617	4,560
	Interest and other finance costs	10	
		5,627	4,56
	Net cash leffew from Financing activities (C)	(5,127	(4,56
L	Net (Decrease) / Increase in cash and cash equivalents (A+6+C)	52	
	Cosh and cash equivalents at the beginning of the period		1
н.	Cash and cash equivalents at the end of the period (I=E)	131	
rv.	Cash and cash equivalents at the end of the period		
	Balances with Bank	134	
	Cash on Hand		
	Cash and cosh equivalents	189	









Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

# To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying Statement of unsulted controlled financial results of Memble Lining ("the Parers") and a subsidiary the Parers and in subsidiary to present and its subsidiary to present a subsidiary to present a subsidiary to present a subsidiary to an interest of the first 01° April 2003 to 95° September, 2023 to 95° Se
- 2. This Sourment, which is the responsibility of the Parent's Management and approved by the Parent's Based of Director, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, "Flad AS 34", "Interim Flasscald Reporting" presented under Section 33 of the Companied Act 2033 has amonded, near with release that is tought thereunder and other accounting principles generally accepted in India. Our responsibility in to exercise sociolation on the Statements based on our review.
- 3. We conclused our evision of the Summers is accordance with the Standards on Review Linguistics (SSIQ 2410). "Science of Internal Fascands disconsists Performed by the Independent Analoss of the Imm" is insued by the Institute of Chantered Accountation of India. This standard expects that we spin and perform that evictive to obtain moderness sensing at an websiter contract of the Indian and perform that evictive to obtain moderness sensing at an uniform consists of minding impairies, parisingly of persons responsible for financial and accounting mattern, and applying subjectly approximately of persons responsible for financial and accounting mattern, and applying subjectly and other review practicals." A review in industrially less in scope that most conducted matter and applying subject to the experimental and accounting matterns. A section is industrially less in scope that most confident on season and consistent an account of the performance of the performance

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Eschange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

#### 4. Emphasis of Matter

We draw settention to note no 2 to the Consolidated financial results regarding the status of disputed biddling ratiated to present golecution (and partner. The said none describes the status of provision made by the company towards total principal amount being Bs. 2(9)(21) lidds for the disputed material (bid algorithm States of Colpans, Colladore of Education) Deg & others. The interest amount discuss in States of the Colpans of the Co

Mistry Bluvur, Sed Fiour, Dhimbras Vachha Road, Churchgane, Mambai 800 (20, Tel: +91 22 6623 0600 501-502, Narain Chumbers, M.G. Road, Vile Parle (F), Mambai 800 755. Tel: +91 22 6250 7600 Website: www.cnkindia.com

MUMBAI | CHENNAI | VADODARA | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

.Our opinion is not modified in respect of above matter.

- The statement includes results of the following entities:

   Alembic City Limited (Substituty)
   Alembic Pharmaceuticals Limited (Associate)
- 6. Based on our review conducted and potentiers performed as rested in paragraph 3-force and based on the consideration referred to its prangary? Johny, modify the core to our restront during cases to believe that the accompaning Sasteman, paramed in accordance, treated to the consumeration of the c
- 70. We did not review the financial intent of a shalidary included in the unsatinat consolidated functions makes, whose unsated functions instead review and mass of \$2.4, \$53,506. high set as 20th September, 2003, send revenue of \$2.4, 41.57 labbs and \$8.005. highs, soul arches after an \$6.5 send of the \$4.5, \$53,066. high set as \$2.5 send of the the quarar could a 50th for the property of the property of the send of the set as \$2.5 send of the send of th

For C N K & Associates LLP

Firm Registration No. 101961W/W-100036

Himanshu Kishnadwala

Membership No.037391 Place: Mumbai Date: 8° November, 2023 UDIN: 23037391BGUMFM3639



Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

## To the Board of Directors of Alembic Limited

- We have reviewed the accompanying Seatement of Unandized Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30th September, 2023 and year to date from 0"th April, 2023 to 30" September, 2023 "the Statement") anaeched herweith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SESI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended the "Listing Regulations".
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles hald down in the Indian Accounting Standard 34, ("Ind AS 347", "Institute Financial Reporting") presented under Section 33s of the Companies Act, 2013 as amended, real with relevant rules issued threeuader and other accounting principles generally accepted in India. Our recognitifiality is to causests an operation on the Statements based on the review.
- 3. We conducted our review of the Statement in scoredance with the Standard on Review Engagements (SLE) 2401, "Review of Interm. Finestal Information Performantly the Independent Auditor of the Engine and Statement of Cantened Accountance of Anka. This stricked intermediate and the Cantened Accountance of Anka. This stricked approach the review of the Statement of Cantened Accountance and Anka. This stricked information is the contract flux of the Statement of Cantened Intermediate Information contints of making inspiritor, primarily of presents responsible for flux occurring mattern, and applying analysis and other review procedure. A review is inspiritating being sense of the statement of the Statement of Cantened Intermediate and contracting and contracting and the Statement of Cantened Intermediate Interme

## 4. Emphasis of Matter

We draw attention to some no 2 to the translation financial travalla regarding the senso of disposal hildsity elected to portuning electricity dury memor. The said most describes the training of provision made by the company towards used principal amount being Rs. 2022.13 halds for the disposal matterly filled against State of Galgare, Coloncor of Electricity Day & others. The interest amount thereon in our extremely and the disposal colonies of Electricity Day & others. The interest amount thereon is not extremely an extra colonies of the Company has been admitted.



Mistry Blavan, Jed Floor, Dinnshow Vachha Road, Churchgane, Mumbui 400 020, Tel: +91 22 6623 0000 501-502, Nazain Chumbers, M.G. Road, Vile Parle (F), Mumbui 400 057, Tel: +91 22 6250 7000 Website: www.encificinis.com

MUMBAI | CHENNAI | VADODARA | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

## Our opinion is not modified in respect of above matter

5. Based on our review conduction as above, revining his come to our attention that cases in no believe that the accompaning Seatement of Counted standardies related worth proposed in accommon with recognition and measurement principles had down in the aforestal Indian Accounting Sensitiates (Find A) Specified under Section 135 of the Companie Ace, 2013 as armitted, read with retrievant rules inseed thereunder and other accounting principles generally accepted in India, has not retrievant rules in the contract of the manner in which, it is to be disclosed, or due it commission are marteral intractinguation.

For C N K & Associates LLP Chartered Accountants

Firm Registration No. 101961W/W-100036

Himanshu Kishnadwala Partner

Membership No.037391 Place: Mumbai Date: 8th November, 2023 UDIN: 23037391BGUMFL4949